* Says purchase price includes debt
* Says acquisition to add to earnings in first year
* Says Hyaluron forecast 2010 rev of $15mln-$17mln
June 15 Albany Molecular Research Inc (AMRI.O)
said it acquired privately held pre-filled syringe maker
Hyaluron Inc for about $27 million to expand its contract
Albany Molecular, which provides drug discovery,
development and manufacturing services, said the $27 million
deal included debt and is expected to add to its earnings
within the first year.
The acquisition will allow Albany Molecular to offer an
integrated manufacturing process for sterile injectable drugs,
including the development and manufacture of the active
pharmaceutical ingredient as well as final products, the
company said in a statement.
Hyaluron provides contract manufacturing services in
sterile syringe and vial filling, and forecast full-year
revenue of $15 million to $17 million.
BroadOak Partners acted as financial advisor to Albany
Molecular, the company said.
Shares of Albany Molecular closed at $5.54 Monday on
(Reporting by Krishnakali Sengupta in Bangalore; Editing by